S&P 500   4,276.80 (-0.26%)
DOW   33,342.48 (-0.49%)
QQQ   360.45 (+0.61%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,276.80 (-0.26%)
DOW   33,342.48 (-0.49%)
QQQ   360.45 (+0.61%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,276.80 (-0.26%)
DOW   33,342.48 (-0.49%)
QQQ   360.45 (+0.61%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
S&P 500   4,276.80 (-0.26%)
DOW   33,342.48 (-0.49%)
QQQ   360.45 (+0.61%)
AAPL   173.72 (+1.47%)
MSFT   318.77 (+0.96%)
META   305.19 (+1.66%)
GOOGL   133.22 (+1.80%)
AMZN   128.77 (+1.30%)
TSLA   248.91 (-0.52%)
NVDA   447.76 (+2.94%)
NIO   8.73 (-3.43%)
BABA   86.20 (-0.62%)
AMD   102.42 (-0.39%)
T   14.88 (-0.93%)
F   12.36 (-0.48%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.23 (-1.19%)
DIS   81.06 (+0.01%)
AMC   7.94 (-0.63%)
PFE   33.16 (-0.03%)
PYPL   59.14 (+1.16%)
NFLX   379.71 (+0.56%)
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Forecast, Price & News

$4.22
-0.08 (-1.86%)
(As of 10:27 AM ET)
Compare
Today's Range
$4.15
$4.36
50-Day Range
$4.00
$4.99
52-Week Range
$1.98
$6.29
Volume
17,248 shs
Average Volume
184,842 shs
Market Capitalization
$180.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Harvard Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.5% Upside
$6.00 Price Target
Short Interest
Healthy
2.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.18mentions of Harvard Bioscience in the last 14 days
Based on 21 Articles This Week
Insider Trading
Acquiring Shares
$109,500 Bought Last Quarter
Proj. Earnings Growth
91.67%
From $0.12 to $0.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Computer And Technology Sector

66th out of 609 stocks

Analytical Instruments Industry

5th out of 29 stocks


HBIO stock logo

About Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Price History

HBIO Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
What Is The History of Harvard Milk Days?
UNH men's soccer team tops Harvard, 1-0
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
436
Year Founded
1901

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+39.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-9,520,000.00
Pretax Margin
-5.67%

Debt

Sales & Book Value

Annual Sales
$113.33 million
Cash Flow
$0.21 per share
Book Value
$1.73 per share

Miscellaneous

Free Float
40,041,000
Market Cap
$183.57 million
Optionable
Optionable
Beta
1.62

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. James W. GreenMr. James W. Green (Age 65)
    Pres, CEO & Chairman
    Comp: $607.35k
  • Ms. Jennifer Cote CPA
    CGMA, CFO & Treasurer
  • Mr. David Balcom
    Sr. VP of Operations
  • Mr. John J. Fry (Age 62)
    Chief Legal Counsel & Corp. Sec.
  • Mr. Ryan Wallace
    Sr. VP of Global Sales
  • Ms. Lori Packer
    VP of Global People Operations
  • David Sirois
    Director of Corp. Accounting & SEC Reporting













HBIO Stock - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings
or view top-rated stocks.

What is Harvard Bioscience's stock price forecast for 2023?

2 brokerages have issued twelve-month price targets for Harvard Bioscience's shares. Their HBIO share price forecasts range from $5.00 to $7.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2023?

Harvard Bioscience's stock was trading at $2.77 at the beginning of 2023. Since then, HBIO stock has increased by 55.2% and is now trading at $4.30.
View the best growth stocks for 2023 here
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HBIO earnings forecast
.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its earnings results on Tuesday, August, 8th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.03. The medical instruments supplier earned $28.76 million during the quarter, compared to the consensus estimate of $29.50 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 3.01% and a negative net margin of 4.76%.

What guidance has Harvard Bioscience issued on next quarter's earnings?

Harvard Bioscience updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $116.00 million-$120.00 million, compared to the consensus revenue estimate of $120.76 million.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $4.30.

How much money does Harvard Bioscience make?

Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $183.57 million and generates $113.33 million in revenue each year. The medical instruments supplier earns $-9,520,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Harvard Bioscience have?

The company employs 436 workers across the globe.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732.

This page (NASDAQ:HBIO) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -